Innocare Pharma
Innocare Pharma, a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in China (CN) and operates extensively across major regions in Asia. Founded in 2015, the company has quickly established itself as a key player in the development and production of innovative therapies, particularly in oncology and autoimmune diseases.
Innocare Pharma is renowned for its unique portfolio of biologics and small molecule drugs, which are designed to address unmet medical needs. The company’s commitment to research and development has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position. With a focus on quality and efficacy, Innocare Pharma continues to make strides in the pharmaceutical landscape, aiming to improve patient outcomes globally.
-16 vs industry average
Innocare Pharma’s score of 22 is lower than 27% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Innocare Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Innocare Pharma's reported carbon emissions
Innocare Pharma's Carbon Emissions and Climate Commitments
Innocare Pharma, a pharmaceutical preparation manufacturing company headquartered in China (CN), has reported its carbon emissions for recent years, focusing primarily on Scope 1 and Scope 2 emissions.
For the year 2023, Innocare Pharma's total reported emissions were approximately 12,134,540 kg CO2e. This figure comprises approximately 19,950 kg CO2e of Scope 1 emissions and approximately 12,114,590 kg CO2e of Scope 2 emissions.
In 2022, the company reported total emissions of approximately 9,835,800 kg CO2e, all attributed to Scope 2. Scope 1 emissions for 2022 were not reported as having data.
For 2021, Innocare Pharma reported total emissions of approximately 9,236,400 kg CO2e, which were entirely Scope 2 emissions. Similar to 2022, Scope 1 emissions data was not available for this year.
In 2020, the company's emissions totalled approximately 2,476,590 kg CO2e, consisting of Scope 2 emissions. Scope 1 emissions for 2020 were reported as zero.
Innocare Pharma's disclosed emissions data currently excludes Scope 3 emissions, with a noted missing data point for purchased goods and services. The company's provided information does not detail any specific absolute reduction targets or achievements in its climate commitments. The available documentation indicates that the company is focused on reporting Scope 1 and 2 emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Innocare Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Innocare Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Innocare Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project